Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
Brandon J. Turunen, Mrinal M. Patnaik(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), James M. Foran(Memorial Sloan Kettering Cancer Center), Craig A. Leach, Stephanie M. Wiltzius, Yael Kusne(WinnMed), Christy M. Finke(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Matthew Smith(Mayo Clinic in Arizona), Aisha Margaert(Sunny BioDiscovery (United States)), Terra L. Lasho(Mayo Clinic)
Cited by 1
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297